CA2213507A1 - Composition pharmaceutique pour le traitement des accidents ischemiques transitoires - Google Patents

Composition pharmaceutique pour le traitement des accidents ischemiques transitoires

Info

Publication number
CA2213507A1
CA2213507A1 CA 2213507 CA2213507A CA2213507A1 CA 2213507 A1 CA2213507 A1 CA 2213507A1 CA 2213507 CA2213507 CA 2213507 CA 2213507 A CA2213507 A CA 2213507A CA 2213507 A1 CA2213507 A1 CA 2213507A1
Authority
CA
Canada
Prior art keywords
group
formula
compound
pyridyl
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2213507
Other languages
English (en)
Inventor
Kaneyoshi Kato
Takenobu Sohma
Zen-Ichi Terashita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2213507A1 publication Critical patent/CA2213507A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composition pharmaceutique destinée au traitement des accidents ischémiques transitoires, comprenant un composé de formule (I) dans laquelle R?1¿ représente un groupe pyridyle, R?2¿ représente un groupe phényle, thiényle, furyle, naphtyle, benzothiényle ou pyridyle, qui peut comporter une substitution par un groupe alcoxy inférieur, un groupe alkyle inférieur, un atome d'halogène, un groupe trifluorométhyle, un groupe alcényle inférieur et/ou un groupe méthylènedioxy, R?3¿ représente un atome d'hydrogène ou un groupe alkyle inférieur, et l représente un entier de 0 à 6, Y est un atome de soufre, un groupe méthylène ou un groupe de formule (a) dans laquelle R?4¿ représente un atome d'hydrogène ou un groupe acétyle, m représentant 0 ou 1, ou un sel pharmaceutiquement acceptable.
CA 2213507 1995-02-22 1996-02-21 Composition pharmaceutique pour le traitement des accidents ischemiques transitoires Abandoned CA2213507A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3396095 1995-02-22
JP7/33960 1995-02-22

Publications (1)

Publication Number Publication Date
CA2213507A1 true CA2213507A1 (fr) 1996-08-29

Family

ID=12401068

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2213507 Abandoned CA2213507A1 (fr) 1995-02-22 1996-02-21 Composition pharmaceutique pour le traitement des accidents ischemiques transitoires

Country Status (4)

Country Link
EP (1) EP0810862A2 (fr)
AU (1) AU4730996A (fr)
CA (1) CA2213507A1 (fr)
WO (1) WO1996025933A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE401082T1 (de) * 2001-09-11 2008-08-15 Asahi Kasei Pharma Corp Medizinische zusammensetzung zur prävention oder behandlung von zerebrovaskulären störungen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0098690B1 (fr) * 1982-06-14 1987-09-09 Takeda Chemical Industries, Ltd. Dérivés d'acides vinylcarboxyliques, leur préparation et leur utilisation

Also Published As

Publication number Publication date
WO1996025933A2 (fr) 1996-08-29
WO1996025933A3 (fr) 1996-10-17
AU4730996A (en) 1996-09-11
EP0810862A2 (fr) 1997-12-10

Similar Documents

Publication Publication Date Title
US20100322869A1 (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
US20120277269A1 (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
JP2010511701A (ja) 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた、発作を含む脳循環の急性および慢性疾患の治療のための手段、それに基づいた薬理学的手段、およびその使用のための方法
TW201136916A (en) New uses
CA3091012A1 (fr) Methode de traitement de la douleur
JP2022511380A (ja) 血清尿酸を低減させるための組成物
RU2336870C2 (ru) Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта
US10383821B2 (en) Colchicine drug-to-drug interactions
US20010003751A1 (en) Pharmaceutical composition for treating transient ischemic attack
NZ534726A (en) Method for treating cognitive disorders usch as Alzheimer's disease using (+)9-N-phenylcarbinol esroline the (+) isomer of phenserine
JP2018508479A (ja) 虚血性脳卒中を予防・治療するための薬物の調製におけるビフェノールの使用
WO2005079792A1 (fr) Agents préventifs ou thérapeutiques pour la rétinopathie diabétique sévère
US20070287685A1 (en) Medicinal composition containing FBPase inhibitor
KR102076137B1 (ko) 수축력 저하 수반성 배뇨근 과활동 개선제
CA2213507A1 (fr) Composition pharmaceutique pour le traitement des accidents ischemiques transitoires
US20080139614A1 (en) Treatment Of Stroke With Histamine H3 Inverse Agonists Or Histamine H3 Antagonists
JPH07188010A (ja) アミロイド形成タンパクの作用を抑制するための医薬組成物
JP2958678B2 (ja) 一過性脳虚血発作抑制剤
US8685952B2 (en) Method for the treatment of diabetes
EA006776B1 (ru) Фармацевтическая композиция для лечения диабетической невропатии
RU2506950C2 (ru) Комбинация карбостирила и карнитина
TW201216977A (en) Compositions and methods for improving brain function
KR20070102694A (ko) 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
TWI432195B (zh) 神經細胞死亡抑制劑
JPH11240834A (ja) 一過性脳虚血発作抑制剤

Legal Events

Date Code Title Description
FZDE Dead